Sec Form 4 Filing - Shendelman Shoshana @ Applied Therapeutics Inc. - 2020-05-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Shendelman Shoshana 2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [ APLT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400 3. Date of Earliest Transaction (MM/DD/YY) 05/28/2020 (Street) NEW YORK, NY10017 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/28/2020 G( 1 ) V 290,280 D $ 0 3,014,005 D Common Stock 02/28/2020 G( 1 ) V 709,720 D $ 0 2,304,285 D Common Stock 02/28/2020 G( 1 ) V 290,280 A $ 0 290,280 I See footnote ( 2 ) Common Stock 02/28/2020 G( 1 ) V 709,720 A $ 0 709,720 I See footnote ( 3 ) Common Stock 1,750,000 I See footnote ( 4 ) Common Stock 05/28/2020 M( 5 ) 27,624 A $ 1 581,909 D Common Stock 05/28/2020 M( 5 ) 97,376 A $ 1.44 679,285 D Common Stock 05/28/2020 S 125,000 D $ 42.7 ( 6 ) 554,285 D Common Stock 88,397 I See footnote ( 7 ) Common Stock 1,492,094 I See footnote ( 8 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1 05/28/2020 M( 5 ) 27,624 ( 9 ) 03/27/2027 Common Stock 27,624 $ 0 0 D Stock Option (Right to Buy) $ 1.44 05/28/2020 M( 5 ) 97,376 ( 10 ) 03/07/2028 Common Stock 97,376 $ 0 629,605 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Shendelman Shoshana C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK, NY10017 X X President and CEO Signatures /s/ Shoshana Shendelman 06/01/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These transactions do not reflect sales, but reflect gifts made for estate-planning purposes from the reporting person to her spouse and/or associated trust. ( 2 )Through a family trust controlled by the reporting person. ( 3 )Through reporting person's spouse. ( 4 )Through a grantor retained annuity trust. ( 5 )These transactions reflect the exercise of previously vested stock options. ( 6 )On May 28, 2020, the reporting person exercised options to purchase 125,000 shares of common stock and sold such shares in a block trade negotiated at a discount from the market closing price of $46.92 per share, for a gross sales price of $42.70. ( 7 )Through Clearpoint Strategy Group LLC of which the reporting person is the sole owner. ( 8 )Through a family trust controlled by the reporting person's spouse. ( 9 )These options became fully vested on April 22, 2019. ( 10 )These options became fully vested on March 7, 2020.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.